Loading
MYC drives half of all cancers but has no pocket for a drug and is needed by normal cells too. The first direct MYC blockers are in trials; the question is whether there is a therapeutic window.
This open question asks whether MYC can be drugged directly and tolerated: MYC drives half of all cancers but has no pocket for a drug and is needed by normal cells too. OMO-103 (Omomyc) showed safety and disease stabilisation in phase 1, and mouse studies showed reversible toxicity in proliferating tissues, but human tolerance at effective doses is unproven. The hypothesis is that transient, intermittent MYC inhibition achieves regression in MYC-amplified cancers while normal tissues recover between doses, and PD-1 blockade may add benefit via CD47 and PD-L1. The test is a randomised phase 2 of OMO-103 plus chemotherapy in MYC-amplified Pancreatic ductal adenocarcinoma and Triple-negative breast cancer (TNBC).
One idea page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited reviews Europe PMC returns for CD47 in Neuroblastoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for CD47 in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Pancreatic ductal adenocarcinoma and the tags mechanism, open-question.
Shares Pancreatic ductal adenocarcinoma and the tags mechanism, open-question.
Shares Triple-negative breast cancer (TNBC) and the tags mechanism, open-question.
Shares Triple-negative breast cancer (TNBC) and the tags mechanism, open-question.
Shares Triple-negative breast cancer (TNBC) and the tags mechanism, open-question.
Shares the tags mechanism, open-question.
Shares the tags mechanism, open-question.
Shares the tags mechanism, open-question.